XTalks

NOVEMBER 9, 2023

Since its approval in May 2022, Mounjaro sales have hit $1.4 In the first half of 2023, sales of Ozempic and Wegovy rose by 58 percent and 363 percent, respectively. “In Zepbound contains mimetics of the GLP-1 and GIP hormones that regulate appetite and blood sugar. billion in just one year and a quarter. billion for Novo.

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

XTalks

MARCH 15, 2023

Norepinephrine is a hormone and neurotransmitter that helps in alertness and maintaining control in high-stress situations. from the previous year owing to the market entry of Strattera generics in the third quarter of 2017. from the previous year owing to the market entry of Strattera generics in the third quarter of 2017.

Drugs 98

Drugs Sales Trials Marketing 98

XTalks

MARCH 22, 2021

The mega biotech acquisition deals, ranging between a quarter to over half a billion dollars, reflects the expanding oncology market, which was valued at $136.7 Despite setbacks due to the pandemic, the market is expected to recover and continue its march forward. The liquid biopsy market itself was valued at over $1.06

Life Science 110

Life Science Development Marketing Gene Expression 110

XTalks

MARCH 8, 2024

Despite the approvals, the market launches of Jubbonti and Wyost are uncertain due to ongoing patent litigation between Sandoz and Amgen. According to Amgen’s last earnings report , Prolia sales increased 12 percent last year to more than $4 billion, and Xgeva’s jumped five percent from last year to $2.1

Drugs 59

Drugs FDA Approval Production Immune Response 59

pharmaphorum

FEBRUARY 3, 2022

Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips for enjoying a big business career. This post looks at dealing with sudden stress and turning it into positive energy. Visualise success. About the author.

Life Science 97

Life Science Hormones Sales Marketing 97

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.

FDA Approval 52

FDA Approval Drugs Sales Development 52

pharmaphorum

JUNE 7, 2022

Exact Sciences is pioneering diagnostics that enable personalised medicine for cancer patients. Additionally, the Oncotype DX® test has been recognised in international healthcare guidelines , and it is these successes in global markets that have paved the way for universal growth. But there is more to be done.

Medicine 72

Medicine Life Science Hormones Doctors 72

The Pharma Data

FEBRUARY 21, 2022

Elinzanetant, a non-hormonal development compound, is currently being investigated in the Phase III clinical development program OASIS for the treatment of vasomotor symptoms during menopause. Every year 47 million women enter menopause, a period where women are at the peak of their life’s activity, personally and professionally.

Radiology 52

Radiology Cardiology Development Production 52

XTalks

NOVEMBER 9, 2022

Glucagon-like peptide-1 (GLP-1) receptor agonists are a newer class of diabetes drugs that have the potential to double as weight loss drugs, widening their lucrative market potentials. Novo’s obesity version of semaglutide (at a higher dose) is marketed as Wegovy and was approved in 2021. And the demand won’t be easing anytime soon.

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

MARCH 25, 2024

They work by mimicking the action of the naturally occurring hormone GLP-1, which is involved in regulating blood sugar and appetite. Access is complex, just like the disease itself is complex,” said Negelle Morris, Novo’s senior VP of cardiometabolic sales. Oprah asked why coverage of weight loss drugs is still limited.

Drugs 105

Drugs Medicine Life Science Cosmetics 105

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. billion in pharmaceutical sales from 2021. billion, a 42.74

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

APRIL 11, 2023

The oncology franchise at Bayer includes six marketed products across various indications and several compounds in different stages of clinical development. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. billion euros. billion euros. Source link: [link]

Research 40

Research Clinical Trials Clinical Trials Trials 40

The Pharma Data

MARCH 11, 2021

The company is taking steps aimed at strengthening sales growth, profitability and free cash flow. At Crop Science we’re targeting above-market growth from 2022. We’re also aiming for above-market growth at Consumer Health. Speeding up sales growth. By 2024, net sales are planned to reach 43 to 45 billion euros.

Sales 52

Sales Gene Therapy Marketing Gene 52

XTalks

MARCH 8, 2021

billion in sales last year, making it the company’s biggest revenue generator in 2020. And now the tirzepatide results could help Lilly continue its market march if it wins approval for it. GLP-1 receptor agonists mimic the action of GLP-1, an intestinal hormone that stimulates the secretion of insulin when blood glucose levels rise.

Insulin 98

Insulin Hormones Clinical Trials Clinical Trials 98

Pharmaceutical Technology

APRIL 24, 2023

. “Biologics products may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system.

Contract Manufacturing 130

Contract Manufacturing Manufacturing Protein Sales 130

XTalks

MAY 20, 2022

And that is a big win for Lilly as it looks to take on diabetes drug rival Novo Nordisk, which currently dominates the market with its diabetes injection Ozempic (semaglutide). Life science industry data analytics company Evaluate Vantage predicts that Mounjaro could bring in $4.9 billion in sales for Lilly by 2026.

Insulin 52

Insulin Life Science Drugs Sales 52